Pharma News

Boehringer Ingelheim announced the results of the LUX-Lung 7 trial. Superiority in progression-free survival and time to treatment failure was demonstrated with second-generation EGFR-directed therapy afatinib, versus first-generation gefitinib in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) with common EGFR mutations (del19 or L858R). The Phase IIb trial met two of its co-primary endpoints of progression-free survival (PFS) by independent review and time to treatment failure (a measure of time between start, and discontinuation of treatment for any reason).

Regularly consuming a soy-rich diet may protect women who are undergoing infertility treatment from poor success rates linked to bisphenol A exposure, a new study suggests.

The Faculty Association of AIIMS (FAAIIMS) has urged Health Minister J.P. Nadda to reinstate two faculty members of the institution, who were removed for allegedly misbehaving and manhandling a patient in 2015.

A team of students from Hebrew University of Jerusalem has developed unique pressure-sensing socks that, when linked to a smart phone app, warn diabetic patients of developing foot ulcers.

A team of US researchers has developed a new biodegradable material with built-in vitamin A which has been shown to reduce scarring in blood vessels.

Amgen  announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira® (adalimumab).

Immunocore, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune disease,  announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead programme, IMCgp100, for the treatment of uveal melanoma. The Orphan Drug status qualifies Immunocore for a number of development incentives and will enable Immunocore to receive fast track registration for IMCgp100, its lead ImmTAC (Immune mobilising mTCR Against Cancer) therapeutic.

[adsense:336x280:8701650588]

Merck , known as MSD outside the United States and Canada,  announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

A Danish citizen has been diagnosed with the Zika virus, making it the first case discovered in Denmark.